Tempus AI Stock Jumps on Merck-Moderna Clinical Trial Breakthrough

Tempus AI shares are trading higher on Friday, with traders reacting to the recent success of Merck and Moderna's clinical trial. The companies' custom mRNA neoantigen therapy, paired with Keytruda, showed improved recurrence-free survival in resected melanoma patients.

This breakthrough is significant because it relies on Personalis Inc.'s genomic tumor-profiling technology, which Tempus AI acquired for $1.5 billion last month after partnering with the firm on minimal residual disease tests.

Tempus CEO Eric Lefkofsky celebrated the news on social media, highlighting the connection between Tempus and Moderna's program.

The stock is currently trading at $70.04, up 5.09% from yesterday's close. However, some analysts are cautioning that the move may be getting 'stretched' as the Relative Strength Index (RSI) reaches overbought territory at 71.53.